🔗 Share this article

Given that the US continues making historic adjustments to its vaccination recommendations, an unexpected name has emerged somewhat surprisingly: Tracy Beth Høeg, a Danish American physician and epidemiologist who initially gained attention by questioning coronavirus vaccines throughout the global health crisis and has focused upon potential deaths following Covid immunization in her brief position at the US Food and Drug Administration (FDA).

Scheduled Overhauls to Pediatric Immunization Schedule

Public health authorities were set to unveil major revisions to the pediatric vaccine schedule earlier this month, aligning the US with the Danish vaccine program, sources say – a major change that would put the US out of alignment with much of the international standard with insufficient data for public health gain. This reveal has been postponed until the new year.

In place of the director of the vaccine center, Høeg is listed to speak at the meeting. She was just designated acting director of the FDA’s drug evaluation center, the fifth individual to run the division this year.

A New Direction at the FDA

This interim role may indicate a tighter collaboration between the pharmaceutical and vaccine centers as Høeg and Dr. Prasad solidify control at the FDA – and it points to a increased emphasis upon reevaluating previously authorized vaccines at the FDA.

The new acting director has repeatedly called for discontinuing certain pediatric vaccine recommendations in the US to become more similar to Denmark, a society with universal health coverage and a citizenry approximately the population of Wisconsin’s.

In her initial statements, she has continued to focus on vaccination policy – traditionally the responsibility of Prasad, chief of the FDA’s CBER – as opposed to pharmaceutical oversight.

Questions Over Expertise

The appointee has little discernible track record in drug development, oversight or management, which has been customary for former leaders of the biologics center. She has served at the FDA as a key advisor to the FDA chief and CBER since earlier this year.

“She appears not to have the necessary background” for overseeing the drug-regulation department, said Jonathan Howard. “She’s never run a clinical trial. She has no expertise in leading a sizeable institution. She lacks background in drug approvals.”

Former directors of CBER would “be deeply familiar with regulatory frameworks and the underlying principles of medication creation”, commented Janet Woodcock. “Clearly, she has not acquired the sort of resume that prior appointees who ran the center have had.”

This division has an immense workload at the agency, the former commissioner stated.

“Many people just zeroes in on the new drug program, but the off-patent medication office clears numerous generic drugs. There’s a biologic copycat branch, OTC medication office and so forth, and each of these need to be supervised,” Woodcock said. “The responsibility you overlook, that is precisely what that I always told people is going to cause problems.”

Furthermore, a major administrative aspect to the role, which oversees more than 5,000 personnel. “It’s a massive administrative position, if you execute it properly,” she added.

Official Statement and Contentious Initiatives

Regarding questions about Høeg’s credentials and whether this selection signifies increased cooperation among agency officials on immunizations, a representative stated that the “inquiries rely on incorrect presumptions”.

“This background matches the responsibilities of her job,” the representative stated, noting the time Dr. Høeg spent guiding the FDA commissioner on “pharmaceutical safety and approval science, including computational safety modeling and vaccine surveillance”.

As the temporary head, Dr. Høeg assumes responsibility for the commissioner’s recently launched expedited review system, a contentious expedited medication authorization process that apparently troubled her predecessors. “By what process are these medications being selected for this expedited pathway? Who makes the choices?” Dr. Howard asked. “There is a lot of secrecy happening at the regulatory body right now.”

Overall, he stated, “the Food and Drug Administration appears to be shifting towards laxer regulations of most medications, with the exception of vaccines.”

Public Past Work on Vaccines

Regarding vaccines, Høeg has a more established, if problematic, history, some experts observe. She published a study using unconfirmed public submissions to estimate the incidence of myocarditis following Covid immunization. She consulted for the state of Florida chief medical officer Dr. Joseph Ladapo, who was said to have changed statistics to suggest Covid vaccines are more dangerous than they are.

Part of her “policy goals” for the incoming administration featured revising regulations for new vaccines and halting “non-essential” immunizations, she remarked following the vote on a online show. At the agency, Dr. Høeg has allegedly suggested barring adolescent males from getting Covid vaccinations.

“She is an complete true believer who begins with her conclusions and reverse-engineers to retrofit the data in a highly deceptive, untruthful way,” Dr. Howard said.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg became part of other skeptics, {like|